9 Meters Biopharma Q3 FY20: net loss $8.3M; diluted EPS −$1.20

Key figures from this report

These are the numbers 9 Meters Biopharma reported for Q3 FY20, the quarter ended Sep 30, 2020, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

1. Net income−$8.3MNo year-earlier figure tagged10-Q income statement, on EDGAR
2. Diluted EPS−$1.20No year-earlier figure tagged. Split-adjusted, as the tables show it; the filing reported −$0.0610-Q income statement, on EDGAR
3. Cash and cash equivalents$12.4MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
4. Cash from operations−$4.2MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters